Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement
Authors
Keywords
-
Journal
PEDIATRIC BLOOD & CANCER
Volume 56, Issue 3, Pages 353-360
Publisher
Wiley
Online
2010-11-28
DOI
10.1002/pbc.22760
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress
- (2010) Girija Dasmahapatra et al. CANCER BIOLOGY & THERAPY
- ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin–DNA adducts
- (2009) Michal Ugarenko et al. BIOCHEMICAL PHARMACOLOGY
- Risk-adapted Treatment of Pediatric Acute Lymphoblastic Leukemia
- (2009) Sima Jeha et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Targeting the Bcl-2 family of proteins in Hodgkin lymphoma:in vitrocytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737
- (2009) Aarthi Jayanthan et al. LEUKEMIA & LYMPHOMA
- ABT-737 Synergizes with Chemotherapy to Kill Head and Neck Squamous Cell Carcinoma Cells via a Noxa-Mediated Pathway
- (2009) R. Li et al. MOLECULAR PHARMACOLOGY
- The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs
- (2009) L. M. High et al. MOLECULAR PHARMACOLOGY
- Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
- (2008) C. Stolz et al. BLOOD
- Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism
- (2008) J. Chen et al. BLOOD
- The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
- (2008) L. Paoluzzi et al. BLOOD
- Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation
- (2008) Blaine W. Robinson et al. BRITISH JOURNAL OF HAEMATOLOGY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
- (2008) M Vogler et al. CELL DEATH AND DIFFERENTIATION
- Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells
- (2008) Mee Young Ahn et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Mechanism of Synergy of N-(4-Hydroxyphenyl)Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation
- (2008) Min H. Kang et al. JNCI-Journal of the National Cancer Institute
- Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway
- (2008) W Zhang et al. LEUKEMIA
- Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene
- (2007) Chie Nishioka et al. LEUKEMIA RESEARCH
- Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
- (2007) Richard Lock et al. PEDIATRIC BLOOD & CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started